Risk factors in antiphospholipid antibody-associated valvular heart disease: A 383-patient cohort study-Reference-Cited by-同舟云学术

Risk factors in antiphospholipid antibody-associated valvular heart disease: A 383-patient cohort study

Published:2023-11 Issue: Volume:256 Page:109790
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Pan Haoyu,Ding Zetao,Yang Zhixia,Tang Zihan,Li Lei,Teng Jialin,Sun Yue,Liu Honglei,Cheng Xiaobing,Su Yutong,Ye Junna,Hu Qiongyi,Chi Huihui,Zhou Zhuochao,Meng Jianfen,Ouyang Binshen,Zhu Yunpeng,Yao Haoyi,Li Jian,Liu Tingting,Yang Chengde,Shi Hui

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference57 articles.

1. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS);Miyakis;J. Thromb. Haemost.,2006

2. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form;Kolitz;Front. Immunol.,2019

3. Heart valve involvement (Libman-sacks endocarditis) in the antiphospholipid syndrome;Hojnik;Circulation,1996

4. A hitherto undescribed form of valvular and mural endocarditis;Libman;Arch. Intern. Med.,1924

5. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on Valvular heart disease;Iung;Eur. Heart J.,2003

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between antiphospholipid syndrome and atrial fibrillation: a single center retrospective case-control study;PeerJ;2024-06-26

2. Assessment of the 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Chinese cohort: Impact on clinical practice;Journal of Autoimmunity;2024-06